SG10202100726XA - Compositions and methods for the depletion of cd117+cells - Google Patents

Compositions and methods for the depletion of cd117+cells

Info

Publication number
SG10202100726XA
SG10202100726XA SG10202100726XA SG10202100726XA SG10202100726XA SG 10202100726X A SG10202100726X A SG 10202100726XA SG 10202100726X A SG10202100726X A SG 10202100726XA SG 10202100726X A SG10202100726X A SG 10202100726XA SG 10202100726X A SG10202100726X A SG 10202100726XA
Authority
SG
Singapore
Prior art keywords
depletion
compositions
cells
methods
Prior art date
Application number
SG10202100726XA
Inventor
Andrew Nixon
Dwight Morrow
Adam Hartigan
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of SG10202100726XA publication Critical patent/SG10202100726XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Diabetes (AREA)
SG10202100726XA 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells SG10202100726XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351725P 2016-06-17 2016-06-17
US201662437729P 2016-12-22 2016-12-22
US201762448782P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
SG10202100726XA true SG10202100726XA (en) 2021-02-25

Family

ID=60119017

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201811290VA SG11201811290VA (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells
SG10202100726XA SG10202100726XA (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201811290VA SG11201811290VA (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells

Country Status (13)

Country Link
US (3) US10111966B2 (en)
EP (1) EP3472178A4 (en)
JP (2) JP7062647B2 (en)
KR (2) KR20190038537A (en)
CN (1) CN109661400A (en)
AU (4) AU2017204125B1 (en)
BR (1) BR112018076306A2 (en)
CA (1) CA3028134A1 (en)
IL (2) IL303455A (en)
MA (1) MA45408A (en)
MX (1) MX2018015684A (en)
SG (2) SG11201811290VA (en)
WO (1) WO2017219029A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3028145A1 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
JOP20190155A1 (en) * 2016-12-21 2019-06-23 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
JP7038717B2 (en) * 2016-12-23 2022-03-18 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Amanitin antibody conjugate
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
US20200188527A1 (en) * 2017-03-31 2020-06-18 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
AU2018302098A1 (en) 2017-07-18 2020-02-20 Csl Behring Gene Therapy, Inc. Compositions and methods for treating beta-hemoglobinopathies
AU2018329066B2 (en) * 2017-09-08 2022-02-17 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Amanitin antibody conjugate
EP3700540A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
EP3717022A4 (en) * 2017-11-29 2021-11-10 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
TW202014209A (en) * 2018-06-20 2020-04-16 瑞士商諾華公司 Antibody drug conjugates for ablating hematopoietic stem cells
JP2021530546A (en) * 2018-07-23 2021-11-11 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
JP2021535092A (en) 2018-08-13 2021-12-16 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Conjoined twins and how to use them
BR112021008437A2 (en) * 2018-10-30 2021-09-28 Magenta Therapeutics, Inc. METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
CA3117816A1 (en) * 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
BR112021012240A2 (en) 2018-12-23 2022-01-18 Csl Behring Llc Hematopoietic stem cell gene therapy for wiskott-aldrich syndrome
CA3134689A1 (en) * 2019-04-24 2020-10-29 Anthony Boitano Conditioning methods for gene therapy
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
EP3959243A4 (en) * 2019-04-24 2023-04-12 Magenta Therapeutics, Inc. Anti-cd117 antibodies and uses thereof
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. Anthracycline antibody-drug conjugates and uses thereof
WO2020219775A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
AU2020336969A1 (en) * 2019-08-29 2022-03-03 Beam Therapeutics Inc. Compositions and methods for non-toxic conditioning
US20230310508A1 (en) * 2020-10-16 2023-10-05 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment with a combination of agents
WO2022099083A1 (en) * 2020-11-06 2022-05-12 Bluebird Bio, Inc. Methods
CN113485489B (en) * 2021-06-18 2022-05-10 淮阴工学院 Method for regulating and controlling outlet temperature of evaporator of ORC system
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451575A (en) 1988-02-19 1995-09-19 J. W. Broadbent Nominees Pty., Ltd. Method of treating liver dysfunction with 24-R scymnol
US5786457A (en) 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
WO1990009799A1 (en) 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
DK0578774T3 (en) 1991-04-05 1999-04-26 Univ Washington Monoclonal antibodies against stem cell factor receptors
WO1993015751A1 (en) 1992-02-14 1993-08-19 Merck & Co., Inc. CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR
EP0703990A4 (en) 1993-04-30 1997-09-24 Lxr Biotechnology Inc Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
ES2174879T3 (en) 1993-09-08 2002-11-16 Imclone Systems Inc MONOCLONAL ANTIBODIES RECOGNIZING FLK-2 RECEPTORS AND ISOLATION OF HEMATOPOYETIC PRIMITIVE MOTHER CELL POPULATIONS.
GB2282812A (en) 1993-10-15 1995-04-19 Merck & Co Inc Cytotoxic/receptor ligand conjugates linked via lysine radicals
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
DE4343261C2 (en) 1993-12-17 1995-11-02 Susanne Holzer Process for the preparation of raw materials for immunoassays and bioassays
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19600589C1 (en) 1996-01-10 1997-01-16 Univ Eberhard Karls Antibody A3C6E2
DE19608769C1 (en) 1996-03-07 1997-04-10 Univ Eberhard Karls Monoclonal antibody BV10A4H2 specific for human FLT3/FLK2 receptor
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
EP0973550B1 (en) 1997-04-11 2002-10-09 G.D. SEARLE & CO. Antagonistic anti-avb3 integrin antibodies
DE19727814C1 (en) 1997-06-30 1998-10-01 Univ Eberhard Karls Monoclonal antibody specific for human tyrosine kinase receptor protein
DE19808453C2 (en) 1998-02-27 2000-12-14 Gsf Forschungszentrum Umwelt Expression vector for the conditional regulation of the expression of the large subunit of RNA polymerase II
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
EP1208219A1 (en) 1999-04-08 2002-05-29 Pavel Sergeev Synthesis of biologically active compounds in cells
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7217811B2 (en) 2000-10-18 2007-05-15 The United States Of America As Represented By The Department Of Health And Human Services Human gene critical to fertility
EP2298878A3 (en) 2000-11-03 2011-11-16 Dana Farber Cancer Institute Compositions and methods for the diagnosis of cancer
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
CN1184890C (en) 2001-10-09 2005-01-19 湖南师范大学 Thuricide engineering bacterium double-effect pesticide containing amatoxin gene
JP2005536180A (en) 2001-12-03 2005-12-02 アブジェニックス・インコーポレーテッド Anti-CD45RB antibodies for use in the treatment of autoimmune diseases and the treatment of transplant rejection
AR037756A1 (en) 2001-12-17 2004-12-01 Bayer Corp ANTIBODY INHIBITING THE ACTIVITY OF THE PRECURSOR CELL FACTOR AND ITS USE FOR THE TREATMENT OF ASTHMA.
US7183385B2 (en) 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US20030232369A1 (en) 2002-04-17 2003-12-18 Bushnell David A. Molecular structure of RNA polymerase II
DE10219866A1 (en) 2002-05-03 2003-11-20 Isolde Riede-Kainrath Treatment and prevention of tumors, using compounds that modulate expression of switch genes or genes for RNA polymerase II, or activity of their products
WO2004002425A2 (en) * 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20060014197A1 (en) 2004-07-15 2006-01-19 Wisconsin Alumni Research Foundation In vivo screening methods for identifying inhibitors of RNA polymerases
CN103251953A (en) 2004-07-19 2013-08-21 约翰·霍普金斯大学 Flt3 inhibitors for immune suppression
EP1661584A1 (en) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
EP1904088A4 (en) 2005-05-24 2010-03-31 Dana Farber Cancer Inst Inc Compositions and methods for the treatment of cancer
US20110014151A1 (en) 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
US20080003224A1 (en) 2006-01-27 2008-01-03 Cellerant Therapeutics, Inc. Compositions and methods for treating haematological proliferative disorders
WO2007121326A2 (en) 2006-04-12 2007-10-25 Crosslink Genetics Corporation Compositions and methods for modulating gene expression
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
ES2371085T3 (en) 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. USE OF AMATOXIN OR FALOTOXIN CONJUGATES WITH MACROMOLECULES FOR TUMOR THERAPY AND INFLAMMATION.
EP3255061B1 (en) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
US20100093008A1 (en) 2007-03-02 2010-04-15 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 (tyr969) and uses thereof
BRPI0812970A2 (en) 2007-06-25 2019-09-24 Endocyte Inc conjugates containing hydrophilic spacers
US20090053168A1 (en) 2007-07-17 2009-02-26 Richard Rickles Treatments of b-cell proliferative disorders
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
WO2010045218A1 (en) 2008-10-13 2010-04-22 Board Of Regents, The University Of Texas System Molecular clock mechanism of hybrid vigor
US8940705B2 (en) 2009-01-09 2015-01-27 The Regents Of The University Of California Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
US9233173B2 (en) 2009-04-08 2016-01-12 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
KR20110140124A (en) * 2009-04-08 2011-12-30 하인즈 파울스티히 Amatoxin-armed target-binding moieties for the treatment of cancer
JP2012528117A (en) * 2009-05-28 2012-11-12 グラクソ グループ リミテッド Targeting stem cells
WO2011026026A1 (en) * 2009-08-31 2011-03-03 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
CN102791865B (en) 2009-12-21 2015-07-01 凯津公司 Improved techniques for transfecting protoplasts
EA027502B1 (en) 2009-12-23 2017-08-31 Зиниммуне Гмбх Anti-flt3 antibodies and methods of using the same
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
KR20110085038A (en) 2010-01-19 2011-07-27 울산대학교 산학협력단 Method for selective depletion of cd137 positive cells using anti-cd137-antibody and toxin complex
CN101861796B (en) 2010-05-18 2012-02-15 四川大学 Method for culturing amanita pantherina by using waste distillage after fermentation of coloured rice
EP2603231B1 (en) 2010-07-13 2021-12-29 Rhode Island Board Of Governors For Higher Education Compositions comprising a pH-sensitive membrane insertion polipeptide.
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
EP2436398B1 (en) 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
US20130288373A1 (en) 2010-12-20 2013-10-31 Kenneth Verstraete Crystal structure of flt3 ligand-receptor complex
CN102526034B (en) 2010-12-24 2015-02-25 四川大学华西医院 Establishment of fulminant liver function failure model of rhesus
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
AR086044A1 (en) 2011-05-12 2013-11-13 Imclone Llc ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
WO2013131927A1 (en) 2012-03-06 2013-09-12 Novartis Ag Combining dna-damaging agents and modulators of actin polymerization for the treatment of cancer
EP2849790B1 (en) 2012-05-15 2019-04-10 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
CN102786586A (en) 2012-07-20 2012-11-21 包海鹰 Discovery of peptide toxins in Amanita pallidorosea fermentation mycelium
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2014043403A1 (en) 2012-09-12 2014-03-20 Agensys, Inc. Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
BR112015006368B1 (en) 2012-09-24 2022-02-08 Medimmune Limited PROCESS FOR PRODUCTION OF STABLE EUKARYOTIC CELL LINE
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
SG11201502896XA (en) 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
CA2896248A1 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
CN105451773A (en) * 2013-03-15 2016-03-30 诺华股份有限公司 Cell proliferation inhibitors and conjugates thereof
MX366978B (en) 2013-03-15 2019-08-01 Novartis Ag Antibody drug conjugates.
BR112015032200A2 (en) 2013-06-24 2017-11-21 Hanwha Chemical Corp antibody-drug conjugate with improved stability, method of preparation, pharmaceutical composition and use thereof
FR3008408B1 (en) * 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
JP6439690B2 (en) 2013-07-12 2018-12-19 石原産業株式会社 Composition for gene transfer into cells
US9718888B2 (en) 2013-07-23 2017-08-01 Ohio State Innovation Foundation Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3065773A1 (en) * 2013-11-05 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Human neutralizing anti-kit antibodies and uses thereof
CN103627757B (en) 2013-12-02 2016-04-13 云南大学 Improve the method for little amanita pantherina mycelium Toxin producing C
CN105377304B (en) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 Amanita hemolysin derivative
JP2017509337A (en) 2014-03-12 2017-04-06 ノバルティス アーゲー Specific sites for modifying antibodies that make immunoconjugates
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10487151B2 (en) 2014-07-23 2019-11-26 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
US10406179B2 (en) * 2014-08-26 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
WO2016036334A1 (en) 2014-09-03 2016-03-10 Şahi̇n Yücel Voltametric methods to determine alpha-amanitin and phalloidin
WO2016061509A1 (en) 2014-10-17 2016-04-21 The Broad Institute, Inc. Compositions and methods of treatng muscular dystrophy
US9938323B2 (en) 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
CN107207564A (en) 2014-11-11 2017-09-26 阿穆尼克斯运营公司 Target XTEN conjugate compositions and preparation method thereof
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
CN107207582A (en) 2015-02-16 2017-09-26 隆萨有限公司 CL and/or CH1 mutant antibodies for drug conjugate
SG11201707097RA (en) 2015-03-04 2017-09-28 Univ Texas Methods of treating cancer harboring hemizygous loss of tp53
EP3268038B1 (en) 2015-03-09 2021-05-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
CN107636016B (en) 2015-03-09 2022-02-11 海德堡医药有限责任公司 Amatoxin-antibody conjugates
WO2016145014A1 (en) 2015-03-10 2016-09-15 President And Fellows Of Harvard College Methods for treatment of autism spectrum disorders
CA2980748A1 (en) 2015-03-25 2016-09-29 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
EP3280720A4 (en) * 2015-04-06 2018-12-05 President and Fellows of Harvard College Compositions and methods for non-myeloablative conditioning
WO2016164745A1 (en) 2015-04-10 2016-10-13 The Methodist Hospital System Cd117 ligand-drug conjugates for targeted cancer therapy
US20180110871A1 (en) 2015-04-17 2018-04-26 Endocyte, Inc. Dual disulfide drug conjugates
CN104862314B (en) 2015-05-11 2017-12-01 昆明理工大学 A kind of and the aptamer of α amanita hemolysin specific bonds and application
EP3297647A1 (en) 2015-05-18 2018-03-28 Universidade Do Porto Use of polymyxin as an antidote for intoxications by amatoxins
AU2016268038A1 (en) 2015-05-22 2017-12-14 Memorial Sloan Kettering Cancer Center Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
US10961308B2 (en) 2015-06-29 2021-03-30 The General Hospital Corporation Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3322449A1 (en) 2015-07-16 2018-05-23 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
AU2016303489B2 (en) 2015-07-31 2023-02-16 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
CN105177009B (en) 2015-08-10 2018-05-25 昆明理工大学 A kind of aptamer and application with α-amanita hemolysin specific bond
SG11201806594QA (en) 2016-02-04 2018-09-27 Suzhou M Conj Biotech Co Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
CN106153768B (en) 2016-06-30 2019-01-01 佛山科学技术学院 Amanita hemolysin molecular engram material is used for the solid phase extraction method of α-amanitin and β-amanitin
JOP20190155A1 (en) * 2016-12-21 2019-06-23 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells

Also Published As

Publication number Publication date
CA3028134A1 (en) 2017-12-21
AU2017204125B1 (en) 2017-10-26
IL263744A (en) 2019-01-31
EP3472178A2 (en) 2019-04-24
IL303455A (en) 2023-08-01
IL263744B2 (en) 2023-11-01
AU2020201138A1 (en) 2020-03-05
AU2018200503A1 (en) 2018-02-15
US20170360954A1 (en) 2017-12-21
WO2017219029A2 (en) 2017-12-21
AU2022202233A1 (en) 2022-04-21
BR112018076306A2 (en) 2019-03-26
AU2018200503B2 (en) 2020-03-05
KR20190038537A (en) 2019-04-08
JP2019522680A (en) 2019-08-15
SG11201811290VA (en) 2019-01-30
JP7062647B2 (en) 2022-05-06
KR20230066647A (en) 2023-05-16
WO2017219029A3 (en) 2018-01-25
EP3472178A4 (en) 2020-02-19
MX2018015684A (en) 2019-08-29
MA45408A (en) 2019-04-24
JP2022106807A (en) 2022-07-20
US20190134217A1 (en) 2019-05-09
US20210162063A1 (en) 2021-06-03
CN109661400A (en) 2019-04-19
AU2018200503C1 (en) 2020-08-27
IL263744B1 (en) 2023-07-01
WO2017219029A8 (en) 2019-01-17
US10111966B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
IL263744A (en) Compositions and methods for the depletion of cd117 plus cells
IL263743A (en) Compositions and methods for the depletion of cells
SG11202003280SA (en) Compositions and methods for the depletion of cd117+ cells
IL268058A (en) Compositions and methods for the depletion of cd137plus cells
EP3700540A4 (en) Compositions and methods for the depletion of cd117+ cells
HK1258041A1 (en) Immune cell compositions and methods of use
HRP20192145T1 (en) Carrier-antibody compositions and methods of making and using the same
HK1250481A1 (en) Modified t cells and methods of making and using the same
IL255932A (en) Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers
HK1244841A1 (en) Methods and compositions for selectively eliminating cells of interest
SG11202004116QA (en) T cell manufacturing compositions and methods
HK1256726A1 (en) Carrier-binding agent compositions and methods of making and using the same
IL269334A (en) Improved t cell compositions and methods
SG11202004294XA (en) Compositions and methods for the depletion of cd5+ cells
SG11202004192XA (en) Compositions and methods for the depletion of cd2+ cells
EP3096742A4 (en) Compositions and methods for modifying the surface of cells and methods of use
GB201711206D0 (en) Compositions and methods of cell attachment
PT3113774T (en) Compositions of grapiprant and methods for using the same
HK1254866A1 (en) Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers
IL251588A0 (en) Methods and compositions for increasing the potency of antifungal agents
GB201518637D0 (en) Cell co-cultures and methods of making the same